Contract Manufacturing Organization BIOTECH Development www.3pbio.com London 23 rd September 15.

Slides:



Advertisements
Similar presentations
1 Integrated Development Pharmaceutical Advisors LLC July 2005.
Advertisements

S4 Select Storage Solutions Scotland State of the art Storage facility offering all ICH and non ICH conditions as required.
Page 1 Private & Confidential NextPharma Technologies Holding Limited Sterile Product Development Centre (SPDC) At Braine-lAlleud, Belgium.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development Best Practices and Application of GMPs for Small Molecule Drugs in.
Bioprocess Pilot Facility
Dock to Stock at Skyline Biotech A brief Outline of how we make our product at Skyline Biotech.
A MBIO P HARM, Inc. Biopharmaceutical Manufacturing and Services.
Reprocessing Biotech Products
GMP Document and Record Retention
A Tech Transfer Case Study From a CDMO
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
Batch Reworking and Reprocessing
Establishing Preclinical Development Operations in China Ming Guo, Ph.D. VP Pharmaceutical Sciences & Manufacturing SABPA Pacific Forum Nov. 4, 2006.
Learning from GMP Inspections. Richard Bateman QA Specialist Pharmacist East and South East England Specialist Pharmacy Services.
Biopharmaceutical Production Biopharmaceutical development and GMP manufacturing Professionally sound Reliable Innovative Open Respectful.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.
Inter-Laboratory Method Transfer
World Health Organization
Custom Synthesis (R&D and cGMP)| Commercialization Expertise |Consulting Services.
Eli Lilly and Company is a world leader in the pharmaceutical industry. We create and deliver innovative pharmaceutical-based health care solutions that.
Number of unit : 3 Course type : Core Prerequisite: None.
World Health Organization
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Quality of Bioequivalence.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
VALIDATION METHODOLOGY
Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics Altogen Labs 4020 S Industrial Dr Suite.
World Health Organization
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
3rd Dimension of Product Translation: Industrialization
PRODUCT TRANSFER.
Gabriela Franco Salinas
A Qualitative Decision Making Tool to Aid in Defining the Number of Lots for a Process Validation Campaign Leslie Sidor — Amgen Inc Midwest Biopharmaceutical.
Topics discussed in the presentation
Establishing the Supply Chain A Small Company Perspective Biomedical Technology Club March 7, 2006.
Facility Drivers for Housing Start-to-Finish Continuous Bioprocessing. Disruptive changes in scale & operational expectations vs. traditional batch operations.
Gabriela Franco Salinas Bas Leewis Rachel Pijls October 5th, 2012 BALANCE-project.
J. Prast, G. Vouters, Arlington, March 2010 DHCAL DIF Status Julie Prast, Guillaume Vouters 1. Future CCC Use in DHCAL Setup 2. Calice DAQ Firmware Implementation.
30/02/2008 Dept. of Pharmaceutics 1 Salient Features of Quality Assurance Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics.
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 1 WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice &
ARETA INTERNATIONAL S.r.l. The Reliable Partner for the Development of Biodrugs in the field of Advanced Therapies.
Pharmaceutical Quality Control & current Good Manufacturing Practice
EUROPEAN RESEARCH AND INNOVATION OFFICE 4 th FLUTCORE Progress Meeting September 23 rd 2015 – London WP9 - Project Management Amelie Guisseau UCL European.
Bioassay Optimization and Robustness Using Design of Experiments Methodology 2015 NBC, San Francisco June 8, 2015 Kevin Guo.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
SRM-DRM ITB Service Integration Plan Jorge Rodriguez OSG Integration Workshop at UC Feb 15-18, 2005.
W w w. g a l c h i m i a. c o m The leading Medchem service provider in Spain.
New Light Path TM Services. slide 2 Light Path TM : streamlined custom material supply for discovery to early development n Leverage Lonza’s proven technology.
Cloning and development of constructs. Cloning overview Construct design Cloning into pPICZ plasmid (bacteria) Yeast cloning (P. pastoris KM71H) Determination.
EUROPEAN RESEARCH AND INNOVATION OFFICE 5 th FLUTCORE Progress Meeting 12 th April, Pamplona (Spain) WP9 - Project Management Cristina Soriano-Carpena.
TECHNOLOGY TRANSFER BATCH Flutcore’s meeting 12 th April 2016.
Julie Kerby, Head of Manufacturing Development Mar 2017
VxP Biologics The Biologics Service Company
נמטוציטים משושנת ים Eli. S Lec. No.2.
Pharmaceutical Quality Control & current Good Manufacturing Practice
3P Biopharmaceuticals 3P Biopharmaceuticals is a European-based Contract Development and Manufacturing Organization (CDMO) specialized in the process development.
Inputs Outputs Tools and Techniques.
Quality Assurance and Quality Control in Generics
Technology Transfer / Consent Decree Remediation
Higher Laboratory Scientist Apprenticeship
Lesson 5: BRITE Seminar: GMP II
The Lifecycle of Pharmaceutical products
PAI Preparation and Readiness
Analytical Method Validation PAI Readiness / Certification
Volume 5, Issue 4, Pages (October 2015)
Clinical Development Process in ICH E5 Environment (1)
Manufacture of Sterile Medicinal Products: Practical Examples
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Manufacturing, Marketing Pharmaceutical development
Presentation transcript:

contract Manufacturing Organization BIOTECH Development London 23 rd September 15

3P OBJECTIVES TECH TRANSFER OF A TANDEM CORE PROTEIN PRODUCTION PROCESS NON- GMP PRODUCTION FOR PRECLINICAL STUDIES GMP PRODUCTION FOR PHASE I CLINICAL STUDIES

3 Documentary tech transfer to 3P Final RCB, characterized (P. pastoris) Final developped Bioprocess: USP and DSP Analytical methods fully developed for IPCs and API analysis (final SOPs). MTA Tech transfer run at sending facility  30L Tech transfer run at 3P  10L Comparability studies TECH TRANSFER TO 3P

4 TIMELINES: Analytical Methods Transference: 16/06/2015 – 13/11/2015 X RCB transference: 24/08/ /09/2015 Tech Transfer at 3P: 30/11/ /02/2015 STATUS: RCB is already at 3P facility. Documentation provided is OK USP: finalized protocol that is being tested at UCL DPS: will be test next week with IQUR. Analytical Methods: pending information (Final Analytics techniques and SOPs)

PHASES: Scale-UP to 100L Non GMP 100L Batch (1 X Engineering Run) NON- GMP PRODUCTION FOR PRECLINICAL STUDIES TIMELINES: Scale Up: 15/02/2016 – 25/03/2016 Engineering Batch: 04/04/ /05/2016

PHASES: Generation and characterization of MCB and WCB Validation of analytical Methods for phase I (ICH Q2) GMP production of API DP release GMP PRODUCTION FOR CLINICAL STUDIES TIMELINES: Analytical Validation: Depends on Analytical Transference 01/09/ /02/2016 MCB/WCB: 14/11/2015– 25/03/2016 (including the final characterization) GMP Batch: 30/05/ /07/2016 Final release: 15/07/2016

Polígono Mocholí, c/ Mocholí nº Noáin (NAVARRA) SPAIN T F AV_V4